Wanbury Ltd Stock Price Today (NSE: WANBURY)
Fundamental Score
Wanbury Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Wanbury Ltd share price today is ₹267.95, down 0.20% on NSE/BSE as of 17 June 2026. Wanbury Ltd (WANBURY) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹895.00 (Cr). The 52-week high for WANBURY share price is ₹314.90 and the 52-week low is ₹161.50. At a P/E ratio of 20.82x, WANBURY is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 76.52% and a debt-to-equity ratio of 3.02.
Wanbury Ltd Share Price Chart — NSE/BSE Historical Performance
Wanbury Ltd share price chart: 3.48% return over the past month. 52-week high ₹314.90, 52-week low ₹161.50.
Wanbury Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹252.65 | ₹261.55 | ₹249.10 | ₹260.60 | 69.78K (Cr) | |
| ₹259.95 | ₹262.90 | ₹246.60 | ₹249.10 | 51.98K (Cr) | |
| ₹256.50 | ₹263.00 | ₹249.90 | ₹257.35 | 61.93K (Cr) | |
| ₹253.30 | ₹256.00 | ₹250.10 | ₹253.05 | 12.26K (Cr) | |
| ₹256.50 | ₹257.50 | ₹249.00 | ₹253.35 | 41.39K (Cr) | |
| ₹250.15 | ₹257.95 | ₹247.00 | ₹252.85 | 33.71K (Cr) | |
| ₹250.60 | ₹254.70 | ₹244.15 | ₹250.45 | 45.51K (Cr) | |
| ₹253.95 | ₹264.50 | ₹250.00 | ₹253.50 | 32.35K (Cr) | |
| ₹259.80 | ₹259.80 | ₹253.03 | ₹254.28 | 19.17K (Cr) | |
| ₹261.00 | ₹264.00 | ₹255.20 | ₹257.96 | 39.48K (Cr) |
Wanbury Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹253.95 | ₹264.50 | ₹244.15 | ₹260.60 | +2.62% | |
| ₹232.87 | ₹277.65 | ₹220.50 | ₹254.28 | +9.19% | |
| ₹252.40 | ₹265.35 | ₹217.95 | ₹221.95 | -12.06% | |
| ₹205.30 | ₹284.00 | ₹203.61 | ₹265.61 | +29.38% | |
| ₹225.25 | ₹238.00 | ₹161.50 | ₹208.75 | -7.33% | |
| ₹258.20 | ₹263.90 | ₹225.00 | ₹226.60 | -12.24% | |
| ₹260.05 | ₹274.20 | ₹222.75 | ₹260.25 | +0.08% | |
| ₹257.05 | ₹270.00 | ₹222.00 | ₹262.85 | +2.26% | |
| ₹278.50 | ₹288.45 | ₹244.10 | ₹254.50 | -8.62% | |
| ₹266.00 | ₹309.00 | ₹247.30 | ₹278.30 | +4.62% | |
| ₹281.00 | ₹289.00 | ₹235.40 | ₹268.90 | -4.31% | |
| ₹313.00 | ₹320.95 | ₹265.00 | ₹280.50 | -10.38% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Wanbury Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Wanbury Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WANBURY across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (76.52%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (36.68%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 20.82 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (1197.12%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.46%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (27.81% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (30.94% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹29.50 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
5 factors identified
Elevated Debt Levels (D/E: 3.02)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (2.14x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.80%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (71.73%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Wanbury Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Wanbury Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Wanbury LtdWanbury Ltd...Selected✓ WANBURY • 524212 | 37.6/100 | ₹267.95₹268 | ₹895.00₹895.00 | 20.82Average 20.8 Average | 76.52%Excellent 76.52% Excellent | 36.68%Excellent 36.68% Excellent | 3.02Poor 3.0 Poor | 30.94%Excellent 30.94% Excellent | 10.29%Good 10.29% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Wanbury Ltd PE Ratio History
Historical price-to-earnings ratio for WANBURY — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.98 | ₹226.60 | 25.2x |
| FY 2024 | ₹16.89 | ₹291.18 | 17.2x |
| FY 2022 | ₹25.21 | ₹49.00 | 1.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Wanbury Ltd Quarterly Performance
Latest quarterly metrics for WANBURY — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
24.46%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1197.12%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.29%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
30.94%
Compounded annual net profit growth over 5 years
Wanbury Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for WANBURY — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Wanbury Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Wanbury Ltd (WANBURY) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Wanbury Ltd
About WANBURY (Wanbury Ltd)
Wanbury Ltd is a pharmaceutical company driven by innovation and a commitment to improving healthcare outcomes across the globe. The company formulates, develops, manufactures, and... markets a diverse portfolio of pharmaceutical products including formulations and active pharmaceutical ingredients (APIs). Wanbury addresses a range of therapeutic areas, providing solutions for common and complex health challenges. With a dedication to quality and patient well-being, the company strives to deliver effective and accessible medicines that enhance the lives of people worldwide. Wanbury's integrated approach encompasses research and development, manufacturing excellence, and strategic partnerships, all of which contribute to its sustained growth and success in the competitive pharmaceutical landscape. Wanbury's formulation offerings cover a wide range of medical needs, from managing common ailments to addressing more specialized conditions. Its anti-infective range battles bacterial and viral infections, while its pain and analgesics provide relief for various types of discomfort. Wanbury's product lineup also includes formulations for respiratory conditions, gastroenterological disorders, gynecological health, rheumatological issues, and central nervous system disorders. The company understands the importance of overall health and well-being, and it also provides a comprehensive range of vitamins, minerals, and nutritional supplements. By addressing diverse therapeutic needs, Wanbury plays a vital role in promoting health and improving the quality of life for patients across different demographics. Wanbury's API division plays a crucial role in the pharmaceutical supply chain, providing essential ingredients for a variety of medications. The company manufactures APIs for antidiabetics, helping to manage blood sugar levels in diabetic patients. It also produces APIs for antihistamines, offering relief from allergy symptoms, and for antitussives, which alleviate coughs. Wanbury's API portfolio extends to analgesics, antidepressants, and anti-inflammatory medicines, supporting the production of drugs that address pain, mood disorders, and inflammation. Through its commitment to quality and reliability, Wanbury contributes to the availability of effective and affordable medications, empowering healthcare professionals and patients alike.
Company Details
Key Leadership
Corporate Events
WANBURY Share Price: Frequently Asked Questions
What is the current share price of Wanbury Ltd?
Wanbury Ltd (WANBURY) trades at ₹267.95 on NSE and BSE. Market cap ₹895.00 (Cr). Educational data only.
What is the P/E ratio of Wanbury Ltd?
Wanbury Ltd has a P/E of 20.82x vs industry average 31.77x.
What is the Bull Run score for Wanbury Ltd?
Wanbury Ltd has a Bull Run score of 37.6/100 based on 25+ financial parameters.
Does Wanbury Ltd pay dividends?
Wanbury Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Wanbury Ltd?
Wanbury Ltd has ROE of 76.52%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Wanbury Ltd?
Wanbury Ltd has debt-to-equity of 3.02.
Is Wanbury Ltd a good investment?
Bull Run gives Wanbury Ltd a score of 37.6/100. This is not investment advice — consult a SEBI-registered advisor.